Imaging-Guided Subthalamic Nucleus Deep Brain Stimulation Programming for Parkinson Disease: A Real-Life Pilot Study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 101577149 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2163-0402 (Print) Linking ISSN: 21630402 NLM ISO Abbreviation: Neurol Clin Pract Subsets: PubMed not MEDLINE
    • Publication Information:
      Original Publication: Hagerstown, MD : Lippincott Williams & Wilkins
    • Abstract:
      Background and Objectives: Deep brain stimulation (DBS) is a well-established treatment for Parkinson disease (PD), with programming methods continually evolving. This study aimed to compare the efficacy and patient burden between conventional ring-mode programming (CP-RM) and image-guided volume of tissue activated (IG-VTA) programming for subthalamic nucleus (STN) DBS in PD.
      Methods: In this retrospective study, patients with PD who underwent STN-DBS between 2011 and 2014 (CP-RM group) and 2019 and 2021 (IG-VTA group) were evaluated. The primary outcome was the improvement in the UPDRS III score from preoperative OFF to postoperative ON state without medication at one-year follow-up. Secondary outcomes included hospital stay duration and programming sessions.
      Results: A total of 26 patients were analyzed (IG-VTA: n = 12, CP-RM: n = 14). Both groups showed similar improvements in UPDRS III scores (IG-VTA: 43.62, CP-RM: 41.29). However, the IG-VTA group experienced shorter immediate postoperative hospital stays and fewer hospitalizations after discharge.
      Discussion: IG-VTA programming preserved the clinical efficacy of STN-DBS over 1 year and reduced the patient and clinician burden of hospital stay and programming sessions. However, conclusions drawn must consider the limitations of retrospective design, differing time epochs, and evolving clinical practices. Further multicentric and prospective studies are warranted to validate these findings in the evolving field of neurostimulation.
      Trial Registration Information: The trial is registered on clinicaltrials.gov (NCT05103072).
      Competing Interests: M. Lefranc is a consultant for Boston Scientific, Medtronic, Brainlab, and Zimmer Biomed. M. Tir is a consultant for Boston Scientific. There are no other conflicts of interest specifically related to this manuscript. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.
      (© 2024 American Academy of Neurology.)
    • References:
      Rev Neurol (Paris). 2020 Dec;176(10):770-779. (PMID: 32305141)
      Neurology. 2016 Feb 23;86(8):755-61. (PMID: 26819458)
      Mov Disord. 2016 Aug;31(8):1240-3. (PMID: 27241197)
      N Engl J Med. 2013 Feb 14;368(7):610-22. (PMID: 23406026)
      Mov Disord. 2003 Jul;18(7):738-50. (PMID: 12815652)
      Neurology. 2014 Apr 15;82(15):1352-61. (PMID: 24647024)
      Acta Neurochir (Wien). 2012 Nov;154(11):2069-74. (PMID: 22814648)
      Mov Disord. 2017 Oct;32(10):1380-1388. (PMID: 28843009)
      Mov Disord. 2020 Dec;35(12):2261-2269. (PMID: 32979290)
      J Am Geriatr Soc. 2005 Apr;53(4):695-9. (PMID: 15817019)
      Neuroimage. 2011 Feb 1;54(3):2096-104. (PMID: 20974269)
      J Neurol Neurosurg Psychiatry. 2014 Oct;85(10):1167-73. (PMID: 24249783)
      World Neurosurg. 2023 Feb;170:54-63.e1. (PMID: 36435384)
      Mov Disord. 1999 Jul;14(4):572-84. (PMID: 10435493)
      J Neurosurg Sci. 2024 Feb;68(1):59-69. (PMID: 32031356)
      Stereotact Funct Neurosurg. 2021;99(5):425-442. (PMID: 34120117)
      Mov Disord. 2018 Aug;33(8):1248-1266. (PMID: 29570866)
      Neuromodulation. 2022 Aug;25(6):817-828. (PMID: 34047410)
      J Psychiatr Res. 1975 Nov;12(3):189-98. (PMID: 1202204)
      Mov Disord. 2010 Nov 15;25(15):2649-53. (PMID: 21069833)
      J Neurosurg. 2020 Oct 23;135(2):611-618. (PMID: 33096524)
      Nat Rev Neurol. 2021 Feb;17(2):75-87. (PMID: 33244188)
      World Neurosurg. 2018 Sep;117:e692-e697. (PMID: 29945003)
      World Neurosurg. 2017 Oct;106:602-608. (PMID: 28735132)
      JAMA. 2009 Jan 7;301(1):63-73. (PMID: 19126811)
      Neuromodulation. 2023 Feb;26(2):348-355. (PMID: 35088739)
    • Molecular Sequence:
      ClinicalTrials.gov NCT05103072
    • Publication Date:
      Date Created: 20240916 Latest Revision: 20240918
    • Publication Date:
      20240918
    • Accession Number:
      PMC11396028
    • Accession Number:
      10.1212/CPJ.0000000000200326
    • Accession Number:
      39282508